Infigratinib Phosphate Patent Expiration

Infigratinib Phosphate was first introduced by Helsinn Healthcare Sa in its drug Truseltiq on May 28, 2021.


Infigratinib Phosphate Patents

Given below is the list of patents protecting Infigratinib Phosphate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Truseltiq US10278969 Pharmaceutical dosage forms Dec 11, 2034 Helsinn Hlthcare
Truseltiq US11160804 Pharmaceutical dosage forms Dec 11, 2034 Helsinn Hlthcare
Truseltiq US8552002 Compounds and compositions as protein kinase inhibitors Aug 25, 2029 Helsinn Hlthcare
Truseltiq US9067896 Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl) -phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof Aug 06, 2028 Helsinn Hlthcare



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Infigratinib Phosphate's patents.

Given below is the list recent legal activities going on the following patents of Infigratinib Phosphate.

Activity Date Patent Number
Patent litigations
Miscellaneous Incoming Letter 23 May, 2024 US8552002
Letter from FDA or Dept of Agriculture re PTE application 16 May, 2024 US8552002
transaction for FDA Determination of Regulatory Review Period 18 Jan, 2024 US8552002
transaction for FDA Determination of Regulatory Review Period 07 Dec, 2023 US8552002
Second letter to regulating agency to determine regulatory review period 09 Mar, 2023 US8552002
Letter from FDA or Dept of Agriculture re PTE application 18 Jan, 2023 US8552002
Payment of Maintenance Fee, 8th Year, Large Entity 30 Dec, 2022 US9067896
Payment of Maintenance Fee, 4th Year, Large Entity 07 Nov, 2022 US10278969
Initial letter Re: PTE Application to regulating agency 28 Jan, 2022 US8552002
Patent Issue Date Used in PTA Calculation 02 Nov, 2021 US11160804


Infigratinib Phosphate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List